CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Vitamin B12 and Methylmalonic Acid Testing

Defines coverage criteria for laboratory testing of vitamin B12 (cobalamin) and methylmalonic acid (MMA), including indications, limitations, and related testing such as holotranscobalamin and homocysteine for Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyVitamin B12 and Methylmalonic Acid Testing

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes in this revision

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionOrder vitamin B12 or MMA testing only when clinical signs, risk factors, or monitoring indications are documented and follow timing limits (e.g., no sooner than 3 months after therapy initiation).

SourceLink

MEETS COVERAGEVitamin B12 testing for symptomatic individuals

MEETS COVERAGEMMA testing to confirm deficiency

DOES NOT MEET COVERAGEHolotranscobalamin testing

>95%Reported MMA sensitivity

<80%Serum total cobalamin specificity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CLIA high-complexity

Coverage Criteria

Covered Indications

Covered when ANY of the following are present:

Signs or symptoms of B12 deficiency: Presence of listed cutaneous, gastrointestinal, hematologic, or neuropsychiatric signs or symptoms (e.g., hyperpigmentation, jaundice, vitiligo, glossitis, macrocytic/megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia/thrombocytosis, areflexia, cognitive impairment, gait abnormalities, irritability, loss of proprioception/vibratory sense, olfactory impairment, peripheral neuropathy)

Source lists specific signs and symptoms

Monitoring therapy: Individuals undergoing treatment for vitamin B12 deficiency, with testing performed no sooner than 3 months after initiation of therapy>=3 months post-initiation

Monitoring timeframe specified

Screening in high-risk individuals: Screening for vitamin B12 deficiency in individuals with one or more risk factors (decreased ileal absorption such as Crohn disease, ileal resection, tapeworm infection, bariatric surgery; decreased intrinsic factor such as atrophic gastritis, pernicious anemia, postgastrectomy syndrome; genetic causes such as transcobalamin II deficiency; inadequate intake including alcohol abuse, age >75 years, vegans/strict vegetarians; prolonged medication use such as H2 blockers >12 months, metformin >4 months, proton pump inhibitors >12 months)

Multiple specific risk factors enumerated

MMA and Metabolic Indications

Covered when ANY of the following are met:

MMA for confirmation: In asymptomatic high-risk individuals with low-normal vitamin B12 or when vitamin B12 deficiency is suspected but the serum vitamin B12 level is normal or low-normal, methylmalonic acid testing to confirm deficiency meets coverage criteria

Used as confirmatory test

Inborn errors of metabolism: Methylmalonic acid testing meets coverage criteria for evaluation of inborn errors of metabolism

Diagnostic use in metabolic disorders

Indications and monitoring criteria

Covered when testing is indicated according to specialty guideline clinical scenarios and perioperative/bariatric monitoring recommendations.

Clinical indications per guideline: Testing for serum vitamin B12 is indicated for patients with suspected deficiency manifested by dermatologic findings (hyperpigmentation, jaundice, vitiligo), gastrointestinal signs (glossitis), hematologic abnormalities (macrocytic/megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia, thrombocytosis), or neuropsychiatric findings (areflexia, cognitive impairment including dementia-like symptoms, gait abnormalities, irritability, loss of proprioception/vibration, olfactory impairment, peripheral neuropathy)

AAFP manifestations list

Risk-factor based testing per guideline: Testing is indicated in patients with risk factors such as decreased ileal absorption (Crohn disease, ileal resection, tapeworm infection), decreased intrinsic factor (atrophic gastritis, pernicious anemia, postgastrectomy syndrome), genetic causes (transcobalamin II deficiency), inadequate intake (alcohol abuse, age >75 years, vegans/strict vegetarians), and prolonged medication use (H2 blockers >12 months, metformin >4 months, proton pump inhibitors >12 months)

AAFP risk factors

Bariatric surgery pre- and post-op monitoring:

Screening for vitamin B12 deficiency in healthy, asymptomatic individuals does not meet coverage criteria. Testing in the absence of symptoms or risk factors may be denied, and clinical documentation should support any exception based on the policy's listed indications and risk factors.

Holotranscobalamin (holoTC) testing for the screening, testing, or confirmation of vitamin B12 deficiency does not meet coverage criteria and is not a covered diagnostic option under this policy.

Homocysteine testing used for confirmation of vitamin B12 deficiency does not meet coverage criteria. Because homocysteine is less specific than methylmalonic acid (MMA), it is not supported as a confirmatory test in this policy.

Available evidence does not support using vitamin B12 supplementation for primary prevention of cardiovascular disease. Meta-analyses and systematic reviews reported reductions in homocysteine but no demonstrable decrease in cardiovascular events, and vitamin B12 should not be used for cardiovascular disease prevention.

Do not initiate folic acid treatment without first checking for and, if present, treating vitamin B12 deficiency. The policy highlights that folic acid can mask or precipitate neurologic deterioration (including subacute combined degeneration), and guidance for perioperative, obstetric, and other at-risk populations recommends confirming B12 status prior to additional folic acid supplementation.

Use of homocysteine testing to confirm vitamin B12 deficiency is not medically necessary under this policy. The document states that homocysteine is less specific than methylmalonic acid and therefore does not meet criteria as a confirmatory diagnostic test.

Routine population screening of average-risk, asymptomatic persons for vitamin B12 deficiency is not recommended and does not meet coverage criteria. Screening should be limited to individuals with symptoms or documented risk factors described in the policy (for example, malabsorption, older age, strict vegetarian diet, or prolonged medication use).

Covered Indications and Diagnostic Use

Diagnostic testing for symptomatic patients, monitoring therapy (>=3 months), screening/diagnostic testing in high-risk individuals, MMA for confirmation and inborn errors of metabolism.

Covered when ANY of the following are present:

Symptomatic diagnostic testing: Diagnostic testing for patients with signs or symptoms consistent with vitamin B12 deficiency (see listed cutaneous, gastrointestinal, hematologic, or neuropsychiatric manifestations)

Meets coverage for symptomatic patients

Treatment monitoring: Monitoring of individuals receiving vitamin B12 therapy, with testing no sooner than 3 months after initiation of therapy>=3 months post-initiation

Timing requirement for monitoring

Screening/diagnostic testing in high-risk individuals: Screening or diagnostic evaluation in individuals with one or more risk factors (decreased ileal absorption, decreased intrinsic factor, genetic causes, inadequate intake, prolonged medication use, advanced age, vegan diet) meets coverage criteria

Frequency Limits and Monitoring Intervals

inv-39: Vitamin B12 testing for treatment monitoring — No sooner than 3 months after initiation of therapy.

TimingNo sooner than 3 months after initiation of therapy

ContextApplies to individuals undergoing treatment for vitamin B12 deficiency for monitoring response to therapy

DocumentationClinical documentation should support treatment initiation date to justify timing of post-treatment testing

inv-40: serum B12 (MMA/HCy optional or indicated in certain contexts) — Baseline pre-op; postoperative checks at 3, 6, and 12 months in first year, then at least annually (or q3-6 months if supplemented each visit).

PreoperativeBaseline pre-op serum B12 assessment is recommended for all bariatric surgery patients

Postoperative schedule (first year)

Provider Actions and Requirements

Documentation Required

Benefit-dependent coverage

Coverage is benefit-dependent. Application of coverage criteria for Vitamin B12 and MMA testing depends on the individual's benefit coverage at the time of the request. Medicare and Medicaid specifications are referenced elsewhere in this policy (see Section VII).

Coverage determination depends on member's benefit at time of request
Medicare/Medicaid specifications referenced in Section VII

Documentation Required

Laboratory certification and LDT regulation

Laboratories performing Laboratory-Developed Tests (LDTs) must meet applicable regulatory and quality standards. LDTs are regulated by CMS as high-complexity tests under CLIA '88; they are not FDA-cleared/approved for most LDT uses, and FDA clearance is not currently required for clinical use.

LDTs regulated by CMS as CLIA high-complexity tests
LDTs generally are not FDA-approved/cleared; FDA clearance not currently required for clinical use

Ordering Requirements

Documentation Required

Attach clinical indication or risk factors to orders

Order requests should be accompanied by the clinical indication or risk factors described in the policy to support medical necessity.

Note

Order B12/MMA based on manifestations or bariatric care pathway

Order tests when clinical manifestations or documented risk factors are present; include B12 testing as part of bariatric preoperative evaluation and scheduled postoperative surveillance.

ASMBS and related guidelines recommend routine pre-WLS screening and postoperative monitoring for RYGB, SG, and malabsorptive procedures.

Documentation Required

Collect recommended pre-treatment samples and follow monitoring protocols

Obtain appropriate pre-treatment plasma and urine samples for MMA, methionine, folate, and vitamin B12 when evaluating suspected remethylation disorders and follow recommended monitoring intervals for bariatric patients.

Not Covered Services

Holotranscobalamin testing for the screening, testing, or confirmation of vitamin B12 deficiency is explicitly listed as not covered under this policy and may be denied if billed for those purposes.

Screening of healthy, asymptomatic individuals for vitamin B12 deficiency is not covered. Organizations referenced in the policy do not recommend average-risk population screening; coverage is reserved for symptomatic patients or those with documented risk factors.

Homocysteine testing for confirmation of vitamin B12 deficiency does not meet coverage criteria and is listed among tests that are not covered for that specific purpose.

Using vitamin B12 testing or supplementation as a strategy for cardiovascular disease prevention is not supported by the evidence summarized in the policy and routine population screening for this purpose is not covered.

No additional specific tests are listed as not covered in the referenced sections beyond those already identified (holoTC, homocysteine, asymptomatic screening). Laboratories performing laboratory-developed tests must comply with CLIA requirements, but the policy does not enumerate further noncovered assays in these chunks.

Coding and Thresholds

inv-11: Serum total cobalamin cutoff value.

Cutoff valueSerum total cobalamin <200 pg/mL

SensitivityReported sensitivity 95-97% for <200 pg/mL

SpecificityReported specificity <80% for <200 pg/mL

inv-12: MMA cutoff cited in newborn study.

Cutoff valueSerum MMA cutoff cited in newborn study: 0.423 µM

Study performanceReported specificity 0.90 and sensitivity 0.91 in newborns (Rozmarič et al., 2020)

ContextUsed as an indicator of B12 deficiency in newborn screening algorithms

Definitions and Background

Vitamin B12 (cobalamin) is essential for hematologic and neurologic function and for DNA synthesis. When vitamin B12 is unavailable at the cellular level, the metabolite methylmalonic acid (MMA) accumulates; elevated MMA is therefore considered an indicator of functional B12 deficiency and is used as a more specific second‑line test when serum B12 results are low‑normal or discordant with clinical findings.

inv-28: Definition — Methylmalonic acid (MMA) accumulates when vitamin B12 is unavailable.

DefinitionMethylmalonic acid (MMA) is produced from excess methylmalonyl-CoA that accumulates when vitamin B12 is unavailable

Clinical roleConsidered an indicator of functional B12 deficiency and used as a confirmatory second-line test

PitfallsElevated MMA may be influenced by renal insufficiency and congenital metabolic defects

inv-29: Definition — Holotranscobalamin (holoTC) described as metabolically active fraction; emerging marker.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyVitamin B12 and Methylmalonic Acid Testing

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes in this revision

Effective DateJul 1, 2023

Next Review DateN/A

SourceLink

On This Page

Baseline preoperative B12 screening is recommended for all bariatric surgery patients; postoperative monitoring is recommended for RYGB, SG, and malabsorptive procedures with more frequent checks (e.g., every 3 months) in the first postoperative year and then at least annually; consider serum MMA with or without homocysteine when serum B12 may be inadequate

ASMBS, AACE/ACE, BOMSS recommendations

Follow-up when initial testing inconclusive: If serum B12 is normal or low-normal but clinical suspicion persists or complete blood count demonstrates macrocytosis, measure serum methylmalonic acid (MMA) as an appropriate next step; holotranscobalamin is an emerging test but not widely validated or available

AAFP and reimbursement policy guidance

Risk-factor based screening

MMA for confirmation of discordant/low-normal B12: In asymptomatic high-risk individuals with low-normal serum B12 or when B12 deficiency is suspected but serum B12 is normal or low-normal, methylmalonic acid measurement to confirm deficiency meets coverage

Second-tier confirmatory testing

MMA for inborn errors of metabolism: Methylmalonic acid testing meets coverage for evaluation of inborn errors of metabolism

Metabolic disorder evaluation

Suspected vitamin B12 deficiency based on clinical manifestations or presence of risk factors; use MMA when serum B12 is low-normal or discordant.

Covered when ANY of the following are met:

Suspected B12 deficiency by clinical manifestations: Suspected vitamin B12 deficiency based on clinical manifestations such as dermatologic, gastrointestinal, hematologic, or neuropsychiatric findings (refer to policy manifestations list)

AAFP recommended clinical manifestations

Suspected B12 deficiency with risk factors: Presence of risk factors (decreased ileal absorption, decreased intrinsic factor, genetic causes, inadequate intake, prolonged medication use, advanced age) warrant testing

AAFP risk-factor guidance

Low-normal B12 with ongoing suspicion or macrocytosis: When serum B12 is normal or low-normal but clinical suspicion persists or macrocytosis is present, measure serum methylmalonic acid (MMA) as the appropriate next step; holotranscobalamin is emerging but not validated for widespread use

Second-line MMA testing

Preoperative and postoperative monitoring for bariatric surgery patients (baseline pre-op; postop monitoring at specific intervals with increased frequency in first year).

Covered when ANY of the following are met:

Baseline preoperative assessment for bariatric patients: Baseline preoperative vitamin B12 screening is recommended for all bariatric surgery patients

ASMBS/Mechanick guidance

Postoperative monitoring schedule: Postoperative monitoring of vitamin B12 is recommended with checks at 3, 6, and 12 months in the first postoperative year and then at least annually thereafter; more frequent monitoring (e.g., every 3 months) is suggested in the first year and q3-6 months if supplemented early postoperative or by society-specific recommendations3, 6, 12 months then annually

BOMSS/ASMBS suggested frequencies

Use of MMA/HCy adjunctively: Consider serum methylmalonic acid (with or without homocysteine) to identify metabolic B12 deficiency in symptomatic and asymptomatic bariatric patients, in those with history of B12 deficiency, or with preexisting neuropathy

ASMBS recommends MMA adjunctive testing

Increased monitoring for medication-related risk: Patients chronically using medications that exacerbate B12 deficiency risk (nitrous oxide, neomycin, metformin, colchicine, PPIs, seizure medications) should have more frequent monitoring as clinically indicated

ASMBS/BOMSS medication risk guidance

Monitoring and diagnosis of vitamin B12 deficiency including pre-op assessment and periodic postoperative monitoring.

Covered when ANY of the following are present:

Monitoring and diagnosis across contexts: Monitoring and diagnosis of vitamin B12 deficiency including preoperative assessment for bariatric surgery, postoperative periodic monitoring (3, 6, 12 months then annually), assessment in metformin-treated diabetic patients (periodic measurement, especially with anemia or peripheral neuropathy), pregnancy (laboratory surveillance each trimester), and collection of pre-treatment plasma/urine for suspected remethylation disorders

BOMSS/ADA/Remethylation disorder guidelines

Pre-treatment sampling for remethylation disorders: In cases of high total homocysteine or suspected remethylation disorders, obtain plasma and urine samples for determination of MMA, methionine, folate and vitamin B12 before treatment is started

E-HOD consortium recommendation

Metformin-related monitoring: Consider periodic measurement of vitamin B12 levels in metformin-treated patients, especially those with anemia or peripheral neuropathy

ADA recommendation

Check at 3, 6, and 12 months in the first postoperative year

Ongoing monitoringThen at least annually thereafter (or every 3 months in high-risk patients per some societies)

Adjunctive testsConsider serum MMA and/or homocysteine with or without MMA when serum B12 may be inadequate

inv-41: vitamin B12 level — 3, 6, and 12 months in the first year then at least annually.

First-year schedule3, 6, and 12 months in the first year

Long-term scheduleThen at least annually thereafter

PopulationRecommended for patients after sleeve gastrectomy, Roux-en-Y gastric bypass, and malabsorptive procedures

Failure to meet LDT regulatory/validation expectations (e.g., CLIA high-complexity) may impact acceptance/coverage

Documentation Required

Post-treatment timing

Post-treatment testing for vitamin B12 deficiency should be timed to avoid premature assessment of response. Expected intervals to improvement vary by manifestation; for many neurologic improvements the window is up to three months, and guidelines indicate testing no sooner than 3 months after initiation of therapy when assessing treatment response.

AAFP: expected improvement for neurologic symptoms = six weeks to three months
Perform follow-up testing no sooner than 3 months after initiating B12 therapy for treatment response assessment

Documentation Required

Ordering documentation expectations

Ordering providers must document clinical manifestations, signs/symptoms, or risk factors that justify testing for vitamin B12 deficiency. Include appropriate baseline and follow-up testing in bariatric care pathways and other high-risk scenarios.

Document specific signs/symptoms or risk factors when ordering (cutaneous, gastrointestinal, hematologic, neuropsychiatric manifestations listed in guidelines)
Include baseline and postoperative B12 evaluation for bariatric surgery patients (preoperative and regular postoperative monitoring per ASMBS/BOMSS guidance)
In patients with normal or low-normal serum B12 but clinical concern, document need for second-tier testing (MMA and/or homocysteine) as appropriate

Documentation Required

Required clinical sampling and monitoring documentation

When indicated by guidelines or clinical scenario, obtain required pre-treatment plasma and urine samples and perform monitoring as specified. For suspected remethylation disorders or high total homocysteine, obtain plasma and urine for MMA, methionine, folate, and vitamin B12 before initiating treatment.

Obtain plasma and urine samples for determination of MMA, methionine, folate, and vitamin B12 prior to starting treatment in remethylation disorders or when high total homocysteine is present
Document baseline sampling and monitoring in bariatric surgery patients (baseline, 3, 6, 12 months first year, then at least annually as clinically indicated)

Step Therapy

Step therapy

No step therapy requirements are specified in these policy sections. Providers should follow clinical guidance and benefit rules but there are no step-therapy controls described here.

No step therapy requirements described in the provided policy excerpts

Documentation Required

Pre-folic acid B12 testing

Before initiating folic acid supplementation in contexts where folate is being addressed (e.g., preconception, post-bariatric surgery), ensure vitamin B12 status is checked and any B12 deficiency is treated to avoid masking or precipitating neurologic complications.

Check and treat vitamin B12 deficiency before initiating folic acid to avoid precipitating subacute combined degeneration of the spinal cord
Assess B12 status in patients on higher-dose folic acid (>1000 µg/day)

Prior Authorization

Prior authorization

No explicit prior-authorization requirements are specified in these sections. Providers should verify benefit-specific prior authorization rules separately.

Prior authorization: not specified in provided excerpts
Verify member-specific benefit and payer prior authorization portals as needed

Denial Risk

Asymptomatic screening and holoTC

Testing for vitamin B12 deficiency in healthy, asymptomatic individuals is not covered. Holotranscobalamin testing is not covered for screening, testing, or confirmation of vitamin B12 deficiency per this policy.

Screening asymptomatic healthy individuals for B12 deficiency DOES NOT MEET COVERAGE CRITERIA
Holotranscobalamin testing DOES NOT MEET COVERAGE CRITERIA for screening, testing, or confirmation

Recommendation: collect plasma and urine samples before treatment is started in cases of high total homocysteine or suspected remethylation disorders.

Holotranscobalamin (holoTC) is the metabolically active fraction of vitamin B12

Clinical noteAn emerging marker of impaired B12 status but not yet widely validated for routine clinical use

PerformanceMay have slightly better sensitivity than total cobalamin; specificity remains to be determined

inv-30: Definition — Homocysteine as a metabolic by-product; less specific than MMA.

DefinitionHomocysteine is a metabolic by-product whose elevation can be associated with disturbances in B vitamin metabolism

SpecificityLess specific than methylmalonic acid for B12 deficiency

PitfallsLevels may be affected by neurodegenerative disease, malignancy, medications, and other conditions

inv-31: Definition — Holotranscobalamin (duplicate definition entry) — sensitivity similar to total cobalamin; specificity uncertain.

DefinitionHolotranscobalamin (holoTC) is the metabolically active fraction of vitamin B12

PerformanceSensitivity similar to total cobalamin; specificity uncertain

PitfallsLevels may be affected by liver disease, macrophage activation, and autoantibodies

inv-32: Definition — Serum methylmalonic acid (MMA) as a second-line, more direct measure of B12 activity.

DefinitionSerum methylmalonic acid (MMA) is a second-line, more direct measure of vitamin B12 physiologic activity used when serum B12 is low-normal or suspicion persists

Clinical useAppropriate next step when CBC shows macrocytosis or clinical manifestations exist despite normal/low-normal serum B12

Recommendation sourcesAAFP and BC/BS guideline summaries support MMA as second-line testing

inv-33: Definition — Remethylation disorders (list of inherited cobalamin-related disorders).

DefinitionRemethylation disorders include inherited cobalamin-related disorders (cblC, cblD, cblE, cblF, cblG, cblJ) and MTHFR deficiency

Clinical actionObtain plasma and urine samples for MMA, methionine, folate, and vitamin B12 before treatment is started

ContextGuideline-recommended evaluation for suspected remethylation disorders to guide management

inv-34: Definition — Laboratory-developed test (LDT) regulated as high-complexity under CLIA '88.

DefinitionLaboratory-developed test (LDT): a test developed and validated by a laboratory for clinical use

RegulationLDTs are regulated by CMS as high-complexity tests under CLIA '88 and must be validated and performed in-house

FDA statusLDTs are not approved or cleared by the FDA for clinical use; FDA clearance/approval is not currently required